Kanjinti Injection, Powder, Lyophilized, For Solution
Product Images NDC 55513-132

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Kanjinti (NDC 55513-132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1studies 1 And 2: Cumulative Incidence Of Time To First Lvef Decline Of ≥ 10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Kanjinti 01)

A cumulative incidence curve graph showing the time from initiation of Paclitaxel/Trastuzumab treatment (in years) on the x-axis and cumulative incidence on the y-axis. Two groups are compared: AC->T (dashed line) and AC->T+H (solid line), with the number at risk indicated at several time points below the x-axis. The graph includes shaded areas representing variability or confidence intervals around each curve.*

FDA Label Image

Figure 2study 3: Cumulative Incidence Of Time To First Lvef Decline Of ≥ 10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Kanjinti 02)

A cumulative incidence graph comparing observation only versus trastuzumab 1-year treatment over a 24-month period. The x-axis shows time from randomization in months, and the y-axis shows cumulative incidence. Number at risk values are displayed below the x-axis at multiple time points. Two trend lines represent the two treatment groups.*

FDA Label Image

Figure 3study 4: Cumulative Incidence Of Time To First Lvef Decline Of ≥10 Percentage Points From Baseline And To Below 50% With Death As A Competing Risk Event (Kanjinti 03)

A cumulative incidence curve comparing three chemotherapy regimens: AC->T (doxorubicin and cyclophosphamide followed by docetaxel), AC->TH (doxorubicin and cyclophosphamide followed by docetaxel plus trastuzumab), and TCH (docetaxel, carboplatin, and trastuzumab) over 36 months. The x-axis represents time in months, and the y-axis shows cumulative incidence. A risk table with patient counts at various time points is included below the graph.*

FDA Label Image

Figure 4duration Of Disease Free Survival In Patients With Adjuvant Treatment Of Breast Cancer (studies 1 And 2) (Kanjinti 04)

A Kaplan-Meier survival curve chart showing disease-free survival over 3.5 years. The chart compares two treatment groups, one receiving doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab, and the other receiving doxorubicin and cyclophosphamide followed by paclitaxel alone. The y-axis represents the proportion event-free, and the x-axis represents disease-free survival in years. Numbers at risk are indicated below the graph for each group at various time points.*

FDA Label Image

Figure 5duration Of Overall Survival In Patients With Adjuvant Treatment Of Breast Cancer (studies 1 And 2) (Kanjinti 05)

A survival curve chart comparing overall survival over 11 years between two treatments: AC -> T (doxorubicin + cyclophosphamide -> paclitaxel) and AC -> T + H (same regimen plus trastuzumab). The y-axis represents the proportion alive, and the x-axis represents overall survival in years. A table below shows the number of patients at risk at different time points for each group.*

FDA Label Image

Figure 6duration Of Disease Free Survival In Patients With Adjuvant Treatment Of Breast Cancer (study 4) (Kanjinti 06)

A Kaplan-Meier disease-free survival curve chart showing survival probabilities over 5 years for three treatment groups combining different chemotherapy regimens with or without trastuzumab. The x-axis represents disease-free survival in years, and the y-axis represents the proportion event-free. A legend distinguishes the groups by line style with number-at-risk tables below.*

FDA Label Image

Figure 7updated Overall Survival In Patients With Metastatic Gastric Cancer (study 7) (Kanjinti 07)

A survival probability Kaplan-Meier curve illustrating the duration of survival in months for two treatment groups: Fluoropyrimidine + Cisplatin and Fluoropyrimidine + Cisplatin + Trastuzumab. The y-axis shows survival probability, and the x-axis shows months, with censored data points marked by plus signs. The graph includes number at risk tables below the x-axis for both groups.*

FDA Label Image

Principal Display Panelndc 55513-132-01kanjinti™(trastuzumab Anns)for Injection420 mg/vialfor Intravenous Infusion After Reconstitution420 mg/vialcontents:each Carton Contains One 420 mg Kanjinti Multiple-dose Vial.amgen® Store Vial In The Original Carton To Protect From Light In The Refrigerator At2°c To 8°c (36° F To 46°f) Until Time Of Reconstitution.do Not Shake. Do Not Freeze Reconstituted Solution. (Kanjinti 09)

Kanjinti 420 mg/vial (trastuzumab-anns) injection, powder, lyophilized, for intravenous use. The label shows a purple background with the Kanjinti logo and specifies the product strength and formulation. It includes storage instructions to keep the vial in the original carton, protected from light, at 2° to 8°C until reconstitution. The labeler is Amgen, Inc.*

FDA Label Image

Kanjinti 0a

Kanjinti (trastuzumab-anns) injection, powder, lyophilized for solution, 150 mg per vial, intravenous use. The image shows two labels with the Amgen logo, detailing a 150 mg single-dose vial, contents include 150 mg trastuzumab-anns and other excipients. Storage instructions and handling precautions are noted, including not freezing the reconstituted solution and keeping the vial protected from light in a refrigerator at 2°C to 8°C.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.